Financial Survey: Cardio Diagnostics (CDIO) vs. Its Rivals

Cardio Diagnostics (NASDAQ:CDIO) is one of 610 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its competitors? We will compare Cardio Diagnostics to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.

Valuation & Earnings

This table compares Cardio Diagnostics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cardio Diagnostics	$10,000.00	-$6.50 million	-0.52
Cardio Diagnostics Competitors	$859.34 million	$59.85 million	-0.96

Cardio Diagnostics’ competitors have higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Cardio Diagnostics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-40,612.50%	-71.75%	-66.25%
Cardio Diagnostics Competitors	-780.92%	-116.46%	-25.72%

Insider and Institutional Ownership

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 51.4% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 13.3% of Cardio Diagnostics shares are owned by insiders. Comparatively, 13.1% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Cardio Diagnostics has a beta of 2.7, indicating that its share price is 170% more volatile than the S&P 500. Comparatively, Cardio Diagnostics’ competitors have a beta of 1.09, indicating that their average share price is 9% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cardio Diagnostics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1	0	0	0	1.00
Cardio Diagnostics Competitors	7930	12913	39647	1326	2.56

As a group, “MED – BIOMED/GENE” companies have a potential upside of 61.46%. Given Cardio Diagnostics’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Cardio Diagnostics has less favorable growth aspects than its competitors.

Summary

Cardio Diagnostics competitors beat Cardio Diagnostics on 9 of the 13 factors compared.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.